Lancashire and South Cumbria
Formulary
Formulary
4 Central nervous system
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
04-03-03 Selective serotonin re-uptake inhibitors
CSM advice: SSRIs and depressive illness in children and adolescents – see BNF
| Citalopram |
|
Formulary
|
| Tablets (as hydrobromide) 10mg, 20mg Oral drops (as hydrochloride) 40mg/mL (2mg/drop) Note: 8mg(4drops) equivalent in therapeutic effect to 10mg citalopram tablet Citalopram or Sertraline are the antidepressants of choice in epilepsy |
 MHRA: Citalopram and escitalopram: QT interval prolongation MHRA: Citalopram: suspected drug interaction with cocaine; prescribers should consider enquiring about illicit drug use MHRA: SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery |
|
| Escitalopram |
|
Formulary
|
Tablets 5mg, 10mg, 20mg |
|
LSCMMG: Citalopram and escitalopram: QT interval prolongation MHRA: SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery |
|
|
| Fluoxetine |
|
Formulary
|
| Capsules 20mg Liquid 20mg/5mL |
|
MHRA: SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery |
|
|
| Paroxetine |
|
Formulary
|
| Tablets 20mg, 30mg Liquid 10mg/5mL |
|
MHRA: SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery |
|
|
| Sertraline |
|
Formulary
|
Tablets 50mg, 100mg |
|
MHRA: SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery |
|
|
| Vortioxetine Brintellix® |
|
Formulary
|
Tablets 5mg, 10mg, 20mg |
|
MHRA: SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery NICE TA367: Vortioxetine for treating major depressive episodes |
|
|
Links
- LSCMMG: Citalopram and escitalopram: QT interval prolongation
MHRA advice on maximum dose- MHRA caution on use in pregnancy
- MHRA Drug Safety Update Jan 2021: SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery
- MHRA Drug Safety Update Jan 2021: SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery
- MHRA Drug Safety Update Jan 2021: SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery
- MHRA Drug Safety Update Jan 2021: SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery
- MHRA Drug Safety Update Jan 2021: SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery
- MHRA Drug Safety Update Jan 2021: SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery
- MHRA Drug Safety Update Jan 2021: SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery
- MHRA Drug Safety Update July 2016: Citalopram: suspected drug interaction with cocaine; prescribers should consider enquiring about illicit drug use
- MHRA safety advice regarding maximum doses and QT prolongation
- MHRA: Citalopram and escitalopram: QT interval prolongation
- MHRA: Citalopram: suspected drug interaction with cocaine; prescribers should consider enquiring about illicit drug use
- MHRA: SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery
- MHRA: SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery
- MHRA: SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery
- MHRA: SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery
- MHRA: SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery
- MHRA: SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery
- NICE CG116: Post-traumatic stress disorder
- NICE CG134: Depression in children and young people: identification and management
- NICE CG192: Antenatal and postnatal mental health: clinical management and service guidance
- NICE CG206: Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management
- NICE CG222: Depression in adults: treatment and management
- NICE CG31: Obsessive-compulsive disorder and body dysmorphic disorder: treatment
- NICE CG91: Depression in adults with a chronic physical health problem: recognition and management
- NICE TA367: Vortioxetine for treating major depressive episodes
- NICE TA367: Vortioxetine for treating major depressive episodes
- UKMI Q&A: What issues should be considered regarding drug induced QT prolongation?